

# Index

- 1,25 dihydroxy vitamin D *see* calcitriol
- 25-hydroxy vitamin D ..... 53, 54, 117, 191, 223, 264
- absorptiometry *see* dual x-ray absorptiometry
- academic detailing ..... 283, 289
- academic institutions *see* bone health, promoting
- acquired skeletal disorders
- prevalence ..... 81-83
- acromegaly ..... 47
- Actonel *see* risedronate
- adenoma ..... 48, 241, 243
- Administration on Aging ..... 9, 301
- adolescents *see also* children and adolescents ..... 258
- sex hormone deficiency in ..... 48, 191
- adrenal gland ..... 29, 30, 191
- adults *see* young adults; middle age
- adynamic bone disease ..... 54
- Agency for Healthcare Research and Quality (AHRQ) ..... 9, 206, 210, 285
- age-related osteoporosis ..... 43-46
- aging population ..... 4, 6, 76-77, 82-83
- aging *see also* older adults ..... 21, 29, 114
- calcium and ..... 268
  - fall risk and ..... 133
  - nutrition and ..... 268
  - osteoporosis and ..... 43-46
  - physical activity and ..... 129-130, 174-176, 270
- Albright, Fuller ..... 229, 232
- alcohol and bone health ..... 139, 140, 179, 266
- alendronate ..... 226-227, 234
- alkaline phosphatase ..... 190, 191
- allergic disorders ..... 49
- Alzheimer's disease ..... 133
- amenorrhea *see also* athletic amenorrhea ..... 114, 136, 190, 191, 260
- American Academy of Orthopedic Surgeons ..... 177
- American Academy of Pediatrics (AAP) ..... 117
- American Association of Clinical Endocrinology ..... 285

American College of Sports Medicine (ACSM) .....	171
American Geriatrics Society .....	177
American Society for Bone and Mineral Research (ASBMR) .....	337
anabolic therapy <i>see also</i> teriperatide .....	13, 226, 234-236, 274
androgen insensitivity .....	47
anorexia nervosa .....	43, 47, 48, 50, 136, 190, 191, 260
antacids and bone disease .....	53, 54, 264
anticonvulsant medications .....	51, 52, 138-139, 266
antiresorptive therapy <i>see also</i> hormone therapy (HT) .....	13, 25, 50, 210, 226, 226-234, 235-236, 274
as treatment for hyperparathyroidism .....	242
bisphosphonates .....	226-229
calcitonin .....	26, 28, 226, 233
combination .....	233-234, 235-236
selective estrogen receptor modulators (SERMs) .....	219, 226, 232-233
arthritis .....	19, 30, 132, 191
aseptic necrosis .....	50-51
prevalence .....	81
Assessing Care of Vulnerable Elders (ACOVE) .....	287, 294
assessment tools <i>see</i> risk assessment	
athletic amenorrhea .....	47, 48, 124, 136, 190, 191, 260
autoimmune disorders .....	49
avascular necrosis .....	50-51
back braces .....	275
behavior change	
barriers to .....	284-287
need for research on .....	349
benchmarks of physician performance .....	283, 288
bisphosphonates <i>see also</i> drug therapy for osteoporosis, antiresorptive therapy .....	219, 226-229, 243
alendronate .....	226-227, 234
as treatment for osteogenesis imperfecta .....	243
as treatment for Paget's disease of bone .....	55, 242
etidronate .....	228
guidelines for intake .....	228-229
ibandronate .....	228
risedronate .....	226, 228, 234
Blacks <i>see</i> minority groups	
blue sclera (manifestation of osteogenesis imperfecta) .....	57
body weight .....	122, 130-131, 179, 190-191

bone	
architecture .....	17,19
biology of .....	17-35
changes in .....	18, 19, 20-25
composition .....	18
formation .....	20-25
genetic variation in .....	25-26
importance of .....	17-18
life stages .....	113-114
mass .....	18-19
reservoir function .....	17, 18
resorption .....	20-25, 44
structural function .....	17
bone accrual .....	136
Bone Coalition, The .....	337
bone density testing <i>see</i> bone mineral density (BMD) testing	
bone disease	
burden of .....	4, 89-103, 187
causes .....	29-30
costs .....	4, 93-95
disability and .....	93, 96-98
emotional impact of <i>see also</i> depression .....	98-100
family history of as risk factor .....	190, 199
financial impact of .....	6, 93-95, 101
fractures and .....	74-75
genetic abnormalities and .....	29
glucocorticoids and .....	24, 30, 43, 51, 52
hormonal disorders and .....	30
identifying individuals at risk .....	187, 188-198
impact on functional status .....	96-98
impact on individual .....	95-101
impact on quality of life .....	100-101
impact on society .....	89-95
in children and adolescents .....	259-261
lack of awareness .....	4, 7
misperception of .....	4
morbidity and .....	91-93
mortality and .....	89-91, 95-96
nutrition and .....	30
oral health and .....	59
prevalence .....	5, 69-83

prevention .....	220-226
recommendations for screenings .....	198-199
risk assessment .....	266-267, 270-272
risk factors .....	3, 188-192, 271
secondary factors in .....	3, 188, 224-225
treatment and therapy .....	219-244
underdiagnosis of .....	7, 187
bone health .....	25-29
advances .....	3-4, 303
awareness .....	4, 7
determinants of .....	25-26, 111-142
elements .....	25
environmental threats to .....	139, 140
general health linked to .....	349-350
genetic factors .....	111
importance .....	4
in middle-aged and older adults .....	113, 119-120
in young adults .....	114, 118-119
maintaining <i>see</i> lifestyle measures	
menstruation and .....	136, 179, 260
need for national action plan .....	347-348
nutrition and .....	115-122, 159-171
population-based approach to .....	282
pregnancy and lactation and .....	21, 117, 135-136
promoting .....	8-9, 12, 159-180, 347-355
reproductive factors and .....	135-137
status in America .....	12
systems-based approach to .....	281-304
bone health, promoting .....	8-9, 12, 159-180, 347-355
academic institutions' role .....	283, 299, 353-354
clinicians' role .....	283, 284-288
community-based organizations' role .....	352
for children and adolescents .....	256-259
government role .....	283, 296-298, 352-353
health care professionals' role .....	255-275, 351
health care purchasers' role .....	283, 299-300, 352
health plans and insurers' role .....	283, 291-296
health systems' role .....	351-352
hospitals and care facilities' role .....	283, 290-291
importance .....	347
individual and family role .....	350-351

industry role .....	283, 300, 354
medical groups' role .....	283, 288-290
population-based approach .....	13, 311-388
professional associations' role .....	283, 353
public health role .....	283, 296-298, 352-353
systems-based approach .....	13, 281-304
voluntary health organizations' role .....	283, 298-299, 353
bone loss .....	46
causes .....	44
estimated rate of .....	44
bone mass .....	112
ethnic and gender differences in .....	258
physical activity and .....	125, 127
measurement .....	203
bone matrix .....	24
bone mineral density (BMD) testing .....	7, 198-208, 219
and consideration of secondary causes .....	188
and other bone diseases .....	206
complements to .....	208-211
for men .....	199
in adults .....	266-268
gender and ethnic considerations in interpretation of results .....	206
in children and adolescents .....	261
interpretation of results .....	202-206, 267
interpretation of results in older adults .....	272
limitations .....	192, 208
methods .....	200-202, 203
need for .....	198
recommendations .....	192, 198-199, 254, 257, 266, 269-272
time between screenings .....	267, 274
uses of .....	200, 206-208
bone morphogenetic protein .....	33
bone strength	
determinants of .....	19, 30
bone tumors <i>see also</i> cancer, Ewings sarcoma, osteosarcoma .....	57-59, 102
burden of .....	103
mortality and .....	96
osteolytic lesions and osteoblastic lesions .....	59
primary and metastatic .....	57-59
treatment .....	242-243
bone turnover <i>see</i> resorption, markers of bone turnover	

BoneHealth/BodyHealth (BH/BH) .....	330
boron .....	166, 265
breast cancer .....	59, 243
prevalence of associated metastatic bone tumors .....	82
breastfeeding and vitamin D .....	259
British Geriatrics Society .....	177
brittle bone disease <i>see</i> osteogenesis imperfecta	
bulimia .....	260
Burkitt's lymphoma .....	59
caffeine .....	120, 169, 171, 265
calcimimetic agents .....	242
calcitonin .....	26, 28, 226, 233
calcitriol .....	26, 28, 34
as treatment for renal osteodystrophy .....	242
calcium .....	3, 6-7, 12, 17, 26, 29-30, 48, 115-120, 159-164
absorption .....	49, 117
as component of bone .....	18
deficiency .....	190
importance of .....	115-120
in antacids .....	264
lactose intolerance and .....	162, 164
physical activity and .....	118, 119, 124
premature infants and .....	257
recommended intake in adolescents .....	160, 257, 258
recommended intake in adults .....	160, 257, 262, 264
recommended intake in children .....	160, 257, 258
recommended intake in older adults .....	160, 222, 257, 268
regulation .....	26-28
role in frailty stage .....	119
role in growth stage .....	118
role in maintenance stage .....	118-119
self-assessment tools for intake .....	163
sources .....	160-161, 162, 258, 262, 263
sources for older adults .....	268
supplementation .....	116, 120, 163, 219, 262
calcium-regulating hormones <i>see</i> parathyroid hormone, calcitriol, calcitonin	
cancer <i>see also</i> bone tumors, malignancy .....	48
breast .....	59, 243
Burkitt's lymphoma .....	59
in children and adolescents .....	260
leukemia .....	47, 59

lymphoma .....	47, 59
multiple myeloma .....	47, 59, 242-243
myeloma .....	236
non-Hodgkins' lymphoma .....	59
prostate .....	59, 243
carbonated beverages .....	265
causes of bone disease .....	29-30
bacterial infections .....	30
genetic abnormalities .....	29
glucocorticoids .....	30
hormonal disorders .....	30
hypogonadism .....	30
inflammation .....	30
nutritional deficiencies .....	29-30
vitamin D deficiency .....	30
celiac disease .....	49
cement line .....	24
Centers for Disease Control and Prevention (CDC) .....	9, 177-179, 258
Centers for Medicare and Medicaid Services (CMS) .....	9
cerebral palsy .....	50
child abuse, similarity to symptoms of osteogenesis imperfecta .....	57, 260
children and adolescents .....	256-261
bone diseases in .....	260-261
bone growth in .....	20, 113, 118
recommended calcium intake in .....	118, 160, 257-258
recommended vitamin D intake in .....	118, 160, 257
causes of osteoporosis in .....	43
focus on bone health in .....	256
fractures in .....	191, 260
nutrition in .....	256-259
osteogenesis imperfecta in .....	57
osteoporosis in .....	43
physical activity in .....	122-124, 126-127, 128, 172-173, 257, 259
rickets in .....	53-54
with high risk for bone disease .....	259-261
cholesterol	
as similar problem to osteoporosis .....	319
chronic bronchitis .....	51
cirrhosis .....	49
clinical knowledge <i>see also</i> research	
lack of application of <i>see also</i> knowledge-practice gap .....	7

range of .....	11
Cochrane Collaboration .....	129
collagen .....	18, 24
Colles' fractures .....	239
combination antiresorptive therapy .....	226, 233-234
combination antiresorptive/anabolic therapy .....	226, 235-236
community-based organizations <i>see</i> bone health, promoting	
Community Guide <i>see</i> Guide To Community Preventive Services	
Congress .....	9
contraceptives and bone health .....	135, 136-137
copper .....	121, 166, 171, 265
cortical bone .....	19
corticosteroids .....	137-138
cortisol .....	26,29, 50
Crohn's disease .....	49
curriculum development .....	297, 299, 353, 354
Cushing's syndrome .....	30, 47, 48
screening guidelines .....	224
cyclosporine A .....	51, 52, 266
cystic fibrosis .....	47, 48
cystic lesions .....	30
cytokines .....	48
Decade of the Bone and Joint .....	4
Department of Agriculture .....	9
depression .....	47, 50, 97, 100
developmental disabilities .....	50
developmental skeletal disorders .....	55-57
prevalence .....	81
diabetes .....	47, 48
diagnosis of bone disease <i>see also</i> risk assessment, bone mineral density (BMD) testing	
advances in .....	3
inadequacies in .....	7, 187
Dietary Approaches To Stop Hypertension (DASH) .....	121-122, 159
Dietary Guidelines for Americans .....	159
differentiation .....	21
direct-to-consumer advertising.....	317, 319
disease management programs .....	283, 289-290, 300, 354
doctors <i>see</i> health care professionals	
drug therapy for osteoporosis <i>see also</i> treatment and therapy .....	226-237, 272, 274
anabolic therapy .....	13, 234-236, 274
antiresorptive therapy .....	13, 25, 50, 210, 226-234, 274



combination antiresorptive therapy .....	226, 233-234
combination antiresorptive/anabolic therapy .....	226, 235-236
drugs <i>see</i> medications	
dual x-ray absorptiometry (DXA) .....	125, 200-202, 203, 267
use for monitoring .....	200, 206-208
Dubbo Osteoporosis Epidemiology Study .....	193
DXA <i>see</i> dual x-ray absorptiometry	
eating disorders <i>see</i> anorexia nervosa, bulimia	
Elder Floridians Foundation .....	312, 335
elderly <i>see</i> older adults	
emergency medical workers .....	351
emphysema .....	47, 51
endometriosis .....	53
endosteal surface .....	21
epilepsy .....	47, 50, 136
estrogen <i>see also</i> sex hormones; hormone therapy (HT) .....	26, 28, 274
deficiency .....	44, 48
therapeutic use of .....	226, 229-231
ethnic groups <i>see also</i> minority groups, underserved populations	
variation of fracture frequency across .....	72-75
variation of osteoporosis frequency across .....	79-81
etidronate .....	228
European Union Osteoporosis Consultation Panel .....	287
evidence-based practices .....	284, 285
Evista <i>see</i> raloxifene	
Ewing's sarcoma .....	59
exercises beneficial to bone health <i>see also</i> physical activity .....	124, 223
balance exercises .....	122, 130, 172, 174, 177
impact exercises .....	124, 126, 128, 172, 173, 174, 223, 265
mobility exercises .....	130
strength training .....	124, 171, 172, 173, 174, 175, 176, 328, 329
weight bearing .....	122, 171, 172, 173, 174, 175
fall prevention .....	3, 132-135, 177-179, 223-224, 270, 275
environmental hazards .....	133, 177-179
evidence base .....	133-135
importance of .....	132
measures .....	177-179, 223-224
occupational therapists' role .....	270, 275
physical activity and .....	130, 133
physical therapists' role .....	270, 275
recommendations .....	177, 178

fall risk and vitamin D.....	119
falls and bone health, evidence base .....	133-135
falls.....	131-135
causes .....	132
environmental risk factors .....	133, 177-179
evidence base .....	133-135
necessity for inclusion as a factor in BMD assessment screening .....	196-198
prevalence .....	132
prevention <i>see</i> fall prevention	
risk factors .....	132-133, 196-198, 223-224, 270, 275
fiber .....	169
fibrous dysplasia .....	24, 57
fluoride .....	121, 166
followup care	
importance of.....	274
Food and Drug Administration (FDA).....	9
Food and Nutrition Board (FNB) .....	159
formation markers <i>see</i> markers of bone turnover	
formation of bone .....	20-25
Fosamax <i>see</i> alendronate	
FRACTURE index.....	195, 197
fractures <i>see also</i> hip fractures; wrist fractures; spine fractures .....	30, 31, 42
bone disease and .....	74-75
consequences of .....	5, 91-93, 97
costs of .....	5, 93-95, 102
followup for .....	274
history of as risk factor for bone disease .....	190, 195, 199
in children and adolescents .....	191, 260
need for change in paradigm of prevention and treatment .....	348
physical activity and .....	124-125
prevalence .....	5, 69-73, 74, 76-81, 193
prevention .....	270, 274
rehabilitation.....	13, 239-241
risk factors .....	195, 198, 270, 271
treatment .....	13, 237-239
variations in prevalence across ethnic groups .....	72-75
gastrectomy .....	49, 53
gastric bypass surgery.....	49
gastrointestinal diseases and bone disease .....	49, 191
genetic abnormalities and bone disease .....	29
genetic factors of bone health .....	111

glucocorticoid-induced osteoporosis (GIO) .....	24, 51, 52
glucocorticoids .....	29, 30, 43, 49, 51, 52, 191, 266
gonadotrophin-releasing hormone (GnRH) agonists .....	51, 53, 138
government <i>see</i> bone health, promoting	
growth hormones <i>see also</i> insulin-like growth factor .....	25, 26, 29
guideline development .....	283, 299, 353
Guide To Community Preventive Services .....	313
gynecologists <i>see</i> health care professionals	
health care	
fragmented nature of .....	281
problems with current system .....	281
health care professionals <i>see also</i> bone health, promoting .....	6, 12-13, 187, 255-275
need for improvement in prevention and identification .....	7
health care providers <i>see also</i> bone health, promoting	
necessity for long-term coverage .....	292
health education .....	283, 299, 354
Health Plan Employer Data and Information Set (HEDIS) .....	293-294
health plans and insurers <i>see also</i> Medicare .....	8
coverage .....	8, 101, 283
Health Resources and Services Administration (HRSA) .....	9
Healthy People 2010 .....	5, 9, 10, 71, 122, 130
height loss .....	43, 96, 140, 190, 194, 195, 271
hematological disorders <i>see also</i> leukemia, multiple myeloma .....	51
heparin .....	266
hepatitis .....	49
hip fractures <i>see also</i> fractures .....	97-99
mortality and .....	91
rehabilitation .....	239
treatment .....	237-238
hip protectors .....	134-135, 224
Hispanic <i>see</i> minority groups	
HIV .....	49
hormonal disorders .....	30
hormone therapy (HT) <i>see also</i> estrogen .....	13, 28, 229-233, 234, 243
background .....	229
evidence base .....	229-231
future of .....	231-233
hormones <i>see</i> regulatory hormones, sex hormones, growth hormone, thyroid hormone	
hydroxyapatite .....	18
hypercalcemia .....	191-192, 236
hypercalcemia of malignancy .....	21

hyperparathyroidism <i>see also</i> primary hyperparathyroidism .....	24, 30, 47, 190, 191-192, 199, 223, 266
hypocalcemia .....	191
hypogonadism .....	30, 266
hypothyroidism .....	267
hysterectomy and bone health .....	137
ibandronate .....	228
idiopathic hypercalciuria .....	47, 48
idiopathic primary osteoporosis .....	43
causes of .....	43
immobilization .....	47, 51, 172, 191
immuno-suppressants <i>see</i> medications, not bone health-related	
infancy .....	256-257
calcium intake in .....	118, 256-257
inflammation .....	49
Institute of Medicine (IOM) .....	120, 159, 160, 164, 265, 296-297
insulin .....	29
Insulin-like growth factor-1 (IGF-1) <i>see also</i> growth hormone .....	26, 29
insurance <i>see</i> health plans and insurers	
integrin inhibitors .....	236
International Osteoporosis Foundation .....	211
International Society for Clinical Densitometry (ISCD) .....	206
iron .....	121, 166, 171
isoflavones .....	166, 265
joints .....	19
juvenile osteoporosis .....	43
Kaiser Permanente Northwest .....	290
Kallman's syndrome .....	48
kidney disease <i>see</i> renal osteodystrophy	
Klinefelter's syndrome .....	47, 48
knowledge-practice gap .....	6, 7, 8, 285
kyphoplasty .....	238, 293
kyphosis .....	43, 45, 56, 71, 100, 114, 275
lactation <i>see</i> pregnancy and lactation	
lactose intolerance and calcium intake .....	115, 116, 161, 164
lead .....	139, 140
leptin .....	30
leukemia .....	47
lifestyle measures .....	111, 159-180, 222-224, 351
lining cells .....	21
Lipoprotein Receptor Related Protein 5 .....	33, 34

lipxygenase .....	33
liver disease .....	49
Living Healthy .....	323-325, 335
load bearing see mechanical loading	
low bone mass see osteopenia	
lupus .....	47, 49
lymphoma .....	47
macrophage colony stimulating factor (M-CSF) .....	32, 33
magnesium .....	120-121, 160, 165, 166, 171, 265
major depression see depression	
malabsorption .....	49, 50, 53, 191, 266
malignancy .....	51, 57-59
manganese .....	121, 167, 171
markers of bone turnover .....	209-211, 274
to estimate fracture risk .....	210
to estimate rate of bone loss .....	210
to monitor effectiveness of therapy .....	211, 274
to select individuals for therapy .....	210-211
types .....	209-210
uses .....	210-211
marrow fibrosis .....	59
mechanical loading .....	122
and bone strength .....	18
medical conditions that influence bone health .....	47-51, 137-140, 179, 190, 267
Medicare .....	94-95, 101, 291-293
coverage limitations .....	293
coverage of medications .....	293
coverage of testing .....	293
eligibility for testing .....	292
inadequacies in coverage .....	291
role as leader for private insurers .....	292
medications, bone health-related see drug therapy for osteoporosis	
medications, not bone health-related .....	179, 190, 191, 266
bone loss and .....	51, 137-139, 261, 266
fall risk and .....	132-133, 274
interactions with bone density therapy .....	274
role of health care professionals in monitoring .....	274
men, osteoporosis in .....	8, 44-46, 189
menopause and bone health .....	28, 31
menstruation and bone health <i>see also</i> amenorrhea .....	136, 179, 260
meta-analysis .....	225

metabolic bone disease .....	261
prevalence .....	81
metastatic bone tumors <i>see also</i> bone tumors .....	57-59
treatment .....	242-243
methotrexate .....	51, 52, 266
Michigan Osteoporosis Program .....	325-327, 335
micro-architecture .....	32
micro-damage .....	25
middle age .....	257
bone loss and frailty in.....	119-120
nutrition in .....	261-265
<i>Milk Matters</i> Campaign .....	160, 333-334, 335
minerals	
regulation of.....	25-28
minority groups <i>see also</i> ethnic groups, underserved populations	
disparities in access to care .....	8, 301-302
disparities in knowledge .....	8
disparities in quality of care .....	8, 302
fracture prevalence in .....	5, 72-75
modeling .....	20-22
monitoring and surveillance activities .....	283, 298
monitoring therapy .....	206-208, 211, 274
monoclonal gammopathy .....	59
multiple myeloma .....	47, 59, 242-243
mortality and .....	96
prevalence .....	82
multiple sclerosis .....	47, 50
muscle	
activity and bone function .....	19
muscular dystrophy .....	47
musculoskeletal system .....	19
myelofibrosis .....	59
national action plan for bone health .....	347-355
building of science base .....	349
change in paradigm of care for fractures .....	348
importance of stakeholder partnerships .....	354
increase in awareness of bone diseases .....	348
integration of health messages and programs .....	349-350
National Asian Women’s Health Organization (NAWHO) <i>see</i> Living Healthy	
National Bone Health Campaign .....	258, 321-323, 335
National Cholesterol Education Program (NCEP) .....	318-319

National Committee for Quality Assurance (NCQA) .....	293-294
National Guideline Clearinghouse (NGC) .....	285
National Health and Nutrition Examination Survey (NHANES) ...	10, 77, 78, 80, 258
National Hospital Discharge Survey .....	10
National Institute of Aging (NIA) .....	266, 270
National Institute of Child Health and Human Development (NICHD) <i>see also Milk Matters Campaign</i> .....	333, 334
National Institutes of Health Osteoporosis and Related Bone Diseases ~National Resource Center (NIH ORBD~NRC) .....	270, 275, 338
National Osteoporosis Foundation (NOF) .....	192, 193, 194, 199, 206, 211, 271, 285, 302, 337
checklist for risk .....	192, 199
nerve and muscle disease .....	50
neurologic disorders .....	49
New Jersey Department of Health and Senior Services <i>see</i> Project Healthy Bones	
non-Hodgkins' lymphoma .....	59
North Carolina Osteoporosis Support Group .....	329, 330-331
nurses <i>see</i> health care professionals	
nutrition <i>see also</i> calcium; vitamin D; protein .....	12, 29-30, 115-122, 159-171
deficiency and bone disease .....	29-30
in children and adolescents .....	160, 256-259
in older adults .....	160, 268
in young and middle-aged adults .....	160, 261-265
recommended nutrients .....	165-168, 171
OB/GYNs <i>see</i> health care professionals	
occupational therapists .....	270, 275
Office of Disease Prevention and Health Promotion (ODPHP) .....	9
Office on Minority Health (OMH) .....	9
Office on Women's Health .....	9
older adults <i>see also</i> aging .....	254, 257, 268-275
bone loss and frailty in .....	112, 119-120, 129
nutrition in .....	160, 268
physical activity in .....	129-130, 174-176
specialty referrals for .....	275
strength training .....	328, 329
oncogenic osteomalacia .....	54
oophorectomy and bone health .....	135, 137
oral health and bone disease .....	59
orthopedists <i>see also</i> health care professionals .....	351
osteitis fibrosa cystica .....	48
osteoblastic lesions .....	59

osteoblasts .....	21-24
formation .....	21
osteochondroma .....	59
osteoclasts .....	21-25, 34
formation .....	24, 34
osteocytes .....	19, 23, 24, 25
osteogenesis imperfecta (OI) .....	19, 23, 29, 47, 55-57, 102, 260, 261
burden of .....	90, 103
causes .....	29, 56
child abuse symptoms and .....	57, 260
need for awareness of .....	57
prevalence .....	80
treatment .....	243
types .....	56, 58
Osteogenesis Imperfecta Foundation (OIF) .....	337
osteolytic lesions .....	59, 243
osteomalacia .....	12, 19, 30, 49, 53-54, 80, 102, 206, 223
causes .....	50, 53
osteomyelitis .....	30
osteonecrosis .....	50-51
osteopenia .....	5, 56, 77, 204
prevalence .....	6, 76, 79
osteopetrosis .....	29, 57
burden of .....	103
prevalence .....	81
Osteoporosis Risk Assessment Instrument (ORAI) .....	192, 270, 272, 285
Osteoporosis Self-Assessment Tool (OST) .....	193, 270-271, 273, 285
osteoporosis <i>see also</i> age-related osteoporosis; prevention .....	5-6, 41-53, 204, 205
burden of .....	90, 98, 187
causes .....	30-32, 48
classical case .....	41
definition .....	30, 41, 204
development of .....	31-32
drug therapy for .....	24-25, 226-237
fractures and .....	74-75
glucocorticoid-induced .....	24, 43, 51-52
idiopathic primary .....	43
perception of .....	4
prevalence .....	5, 6, 75-81, 205
primary .....	43-45, 46
secondary .....	46-53



underdiagnosis of .....	7, 77
osteoprotegerin .....	33, 34, 243
osteosarcoma .....	55, 59, 102
prevalence .....	81-82
overweight and bone health .....	131
oxalates .....	169
Paget Foundation for Paget's Disease of Bone and Related Disorders, The (TPF) ...	337
Paget's disease of bone .....	4, 7, 12, 24, 30, 54-55, 56, 102
causes .....	30-31, 55
burden of .....	102
prevalence .....	81
treatment .....	242, 243
pamidronate .....	236
parathyroid cancer .....	48
parathyroid hormone (PTH) .....	26, 34, 44, 192, 234
therapeutic use of .....	234-236
parathyroid hormone related protein (PTHrP) .....	26, 59, 237
parathyroidectomy .....	241-242
patient education materials .....	266, 270, 275
patient registries .....	283, 288-289, 299
pay-for-performance initiatives .....	283, 296
pediatricians see health care professionals	
performance assessments .....	283, 293-294
periodontal disease .....	30
periosteal surface .....	21
peripheral DXA (pDXA) .....	201-202, 203
peripheral quantitative computed tomography (pQCT) .....	202, 203
pharmacologic therapy see drug therapy for osteoporosis	
pharmacists see health professionals	
phosphate deficiency .....	53
phosphorus .....	17, 26, 120-121, 160, 165, 167, 169, 171, 259, 265
as component of bone .....	18
danger of excess .....	121, 169, 171
sources .....	171
physical activity see <i>also</i> exercises beneficial to bone health .	3, 6, 7, 12, 19, 20, 122-130, 171-177, 223
bone mass and .....	125
building sustainability in .....	265-266
calcium and .....	118, 119
challenges in studying impact on bone health .....	125
evidence base .....	124-130

falls and fall prevention.....	130
for sedentary patients .....	265-266
fractures and .....	124-125
in adults .....	123, 127-129, 173-174, 175, 265-266
in children and adolescents .....	122-124, 126-127, 128, 172-173, 259
in older adults .....	129-130, 174-176, 270
in those with fragility fractures .....	177
physical therapists' role in .....	270
population-based interventions for .....	313-315
recommendations .....	172, 223, 257, 259, 265, 270
resources .....	328
weight and .....	122
physical therapists .....	270, 275
physician assistants <i>see</i> health care professionals	
Plan, Do, Study, Act (PDSA) cycle.....	288
polycymaking .....	283, 298, 353
poliomyelitis.....	50
population-based interventions .....	11, 311-338
appropriacy to bone health .....	311
communication tools .....	317, 319-320
cultural competence in.....	323-325, 335
definition .....	311
evidence base .....	313
factors in successful .....	334-335, 337
health care systems and .....	335
in combination.....	311
policies as .....	335
program examples .....	320-334
systematic reviews .....	313-317
factors in successfulpopulation-based risk stratification .....	282
postmenopausal osteoporosis <i>see</i> primary osteoporosis	
potassium .....	121, 167
pregnancy and lactation .....	21
breastfeeding and vitamin D .....	259
bone health during.....	117, 135-136
calcium intake during .....	159-160
recommended nutrients during .....	266
premature infants and calcium .....	257
President's Council on Physical Fitness and Sports (PCPFS).....	9
prevention <i>see also</i> treatment and therapy; bone health, promoting .....	3, 6-7
advances in .....	3

as treatment .....	220
in older people .....	6
inadequacy of .....	7
primary .....	220-224
pyramid approach to .....	221-226
secondary .....	188, 220, 221, 224-225
tertiary .....	220, 221, 226-244
primary bone tumors .....	57-59
primary care providers <i>see also</i> health care professionals .....	255, 351
primary hyperparathyroidism .....	48, 81
burden of .....	96, 102
treatment .....	241-243
primary osteoporosis .....	42, 43
primary prevention .....	220-224
product development .....	300, 354
professional associations <i>see</i> bone health, promoting	
professional education .....	13, 283, 286, 289, 297, 299, 353, 354
progesterone <i>see also</i> sex hormones .....	229
Project Healthy Bones .....	327-329, 335
Project Osteoporosis .....	312
prostate cancer .....	59, 243
prevalence of associated metastatic bone tumors .....	82
protein .....	121, 259, 167, 170
as component of bone .....	18
recommended intake .....	264
role in healing fractures .....	264, 268
sources .....	264-265
psychiatric disorders <i>see also</i> anorexia nervosa, major depression .....	50
puberty <i>see</i> children and adolescents	
public awareness campaigns .....	283, 284-285, 296-297, 298-299, 352, 353
public health <i>see</i> bone health, promoting	
pulmonary disease .....	51
purchasing power .....	299-300, 352
pyramid approach to prevention .....	13, 221-226
quality improvement initiatives .....	288, 294-296
quality of life .....	12, 100-107
quantitative computed tomography (QCT) .....	202, 203, 208
quantitative ultrasounds (QUS) .....	202, 203
radiogrammetry .....	202, 203
radiographic absorptiometry (RA) .....	202, 203
raloxifene .....	226, 232

receptor activator of nuclear factor kappa B ligand (RANKL) .....	33, 34
“red flags” <i>see also</i> risk assessment .....	12, 190-192
Regional Health Administrators .....	9
regulatory hormones <i>see also</i> parathyroid hormone, calcitriol, calcitonin, sex hormones	
growth hormones, thyroid hormone, cortisol .....	17, 25-29
and mechanical loading .....	26
rehabilitation of fractures .....	239-241
reimbursement policies <i>see</i> pay-for-performance initiatives	
reminder systems .....	283, 286
remodeling .....	20-25
activation phase .....	23
as damage repair .....	21, 24-25
as lifelong process .....	21
reversal phase .....	23, 24
renal osteodystrophy .....	4, 12, 54, 81, 102-103
treatment .....	242, 243
reproductive factors and bone health <i>see also</i> menstruation and bone health,	
amenorrhea, pregnancy and lactation, oophorectomy .....	135-137
evidence base .....	135-137
research .....	3-4, 11, 353, 354
lack of application <i>see</i> knowledge-practice gap	
design issues .....	225
need for continuation .....	349
population-based .....	349
resorption .....	21, 24, 44
resorption markers <i>see</i> markers of bone turnover	
rheumatic diseases .....	49
rheumatoid arthritis .....	47, 49, 51
rickets .....	4, 12, 19, 30, 53-54, 102, 223, 259
causes .....	53
risedronate .....	226, 228, 234
risk assessment .....	187-212, 266-267, 269
“red flags” signaling need for evaluation .....	190-192
advances in .....	3
current limitations of .....	194
formal tools .....	3, 192-198, 270, 272, 273
importance of .....	187
in adults .....	266-267
in children and adolescents .....	259-261
in older adults .....	270-272
inadequacies in .....	187

next-generation models.....	211-212
risk factors .....	188-192
warning signs.....	260, 266, 271
risk factors for bone disease .....	3, 188-192, 271
amenorrhea .....	114, 136, 190, 191, 260
body weight.....	190-191
family history of bone disease .....	190, 199
genetic factors .....	211-212
height loss .....	190, 194, 195
history of fractures .....	190, 195, 199
kyphosis .....	190
medical conditions .....	191, 199, 260-261, 266
medications .....	190-191, 195, 260, 266
sex hormone deficiency .....	199
smoking .....	199
vitamin D deficiency .....	191, 199
risk factors for fracture .....	195, 270, 271
Rodgers Diffusion Model .....	284-287
ruffled border .....	24
salt <i>see also</i> sodium .....	259, 265
sarcopenia .....	122, 129-130
science base <i>see</i> research .....	
sclerosing bone disorders .....	57
screenings .....	283, 290, 297
secondary causes of bone disease .....	3, 188, 191
importance of treating.....	224
secondary osteoporosis .....	46, 191
secondary prevention.....	188, 220-221, 224-225
selective estrogen receptor modulators (SERMs) .....	219, 226, 232
raloxifene .....	226, 232-233
tamoxifen .....	233
serum calcium measurement .....	191-192, 224
sex hormone binding globulin .....	44
sex hormones <i>see also</i> estrogen, testosterone .....	25, 26, 28-29, 48
deficiency and osteoporosis .....	48, 191
Simple Calculated Osteoporosis Risk Estimation (SCORE) .....	193
single x-ray absorptiometry (SXA) .....	202, 203
small bowel resection .....	53
smoking .....	6, 12, 179, 266
effect on bone health.....	139-140
population-based interventions to reduce .....	315-317

social marketing .....	317
sodium .....	121, 170, 171, 265
specialty clinics .....	283, 289
specialty referrals .....	268, 275, 351
for adults at risk .....	268
for older adults .....	275
to occupational therapists .....	275
to orthopedists .....	275
to physical therapists .....	275
spinal cord injury .....	49
spinal cord lesions .....	51
spine fractures	
costs .....	91, 98, 100
rehabilitation .....	240
treatment .....	238
standing orders for supplements .....	283, 291
statins .....	236
STEPS to a HealthierUS .....	5
steroids <i>see</i> anabolic therapy	
stroke .....	49
strontium ralenate .....	236-237
Study of Osteoporotic Fractures .....	194-195
supplementation .....	3, 7, 12, 257, 268
Surgeon General .....	9-11, 124
sympathetic dystrophy .....	241
systematic risk assessment and intervention .....	283, 290-291
systemic hormones <i>see</i> regulatory hormones	
systems-based approach to bone health .....	13, 281-304, 351
academic detailing .....	283, 289
benchmarks of physician performance .....	283, 288
creation of discipline-specific curricula .....	297, 299, 353, 354
development of guidelines .....	283, 299, 353
disease management programs .....	283, 289-290, 300, 354
evidence-based care .....	283, 284
health education .....	283, 299, 354
improving links between organizations .....	283, 297
insurance coverage .....	283
monitoring compliance with regulations .....	283, 298
patient registries .....	283, 288-289, 299
pay-for-performance initiatives .....	296
performance assessments .....	283, 293-294

policymaking .....	283, 298, 353
product development .....	300, 354
professional education .....	283, 286, 289, 297, 299, 353, 354
public awareness campaigns .....	283, 284-285, 296-297, 298-299, 352, 353
purchasing power .....	299-300, 352
quality improvement initiatives .....	288, 294-296
reminder systems .....	283, 286
research .....	283, 299, 353, 354
screenings .....	283, 290, 297
specialty clinics .....	283, 289
stakeholders <i>see</i> bone health, promoting	
standing orders for supplements .....	283, 291
systematic risk assessment and intervention .....	283, 290-291
T-scores .....	201, 204-207, 261, 267, 272
tacrolimus .....	51, 52, 266
<i>Take Our Trail</i> Physical Activity Program .....	331-333, 335
tamoxifen .....	233
teriparatide .....	226, 235-236, 274
tertiary prevention .....	220, 221, 226-244
testosterone .....	26, 28, 44, 48
thyroid hormone .....	26, 29, 138, 190
excess <i>see</i> thyrotoxicosis	
thyrotoxicosis .....	47, 48, 138
thyrotropin (TSH) .....	29
tobacco use	
population-based interventions to reduce .....	315-317
trabecular bone .....	19, 30
treatment and therapy <i>see also</i> drug therapy for osteoporosis	
as prevention .....	220
disparities in .....	8
future of .....	231-233, 236-237
non-bone medications and .....	274
of bone disease .....	3, 219-244, 272-275
strategies to maximize adherence to .....	267-268, 275
study design issues of .....	225
Turner's syndrome .....	47, 48
U.S. Preventive Services Task Force (USPSTF) .....	198-199, 206, 254, 271, 285
ulcerative colitis .....	49
underserved populations <i>see also</i> minority groups, ethnic groups	
frail elderly .....	302
men .....	302

minorities .....	301-302
rural and inner-city .....	303
underinsured .....	301
uninsured .....	300
underweight and bone health .....	130-131
<i>VERB<sub>TM</sub> It's What You Do</i> campaign .....	320
vertebral fracture <i>see</i> spine fracture	
vertebroplasty .....	238, 293
vitamin A .....	52, 121, 170, 171
vitamin C .....	121, 168, 171
vitamin D .....	3, 6-7, 12, 115-120, 160, 164-165, 222-223
25 hydroxy vitamin D measurement .....	53, 117, 191, 224
breastfeeding and .....	259
deficiency .....	29-30, 49, 50, 53, 191, 199, 223, 259, 264, 268
disorder of and bone disease .....	259
importance of .....	115-120
recommended intake in adults .....	118-119, 160, 257, 264
recommended intake in children .....	118, 160, 257, 259
recommended intake in infants .....	160, 257, 259
recommended intake .....	160, 164, 222-223, 257, 259, 264, 268
sources .....	164-165, 222, 259, 264
sunlight and .....	28, 116-117, 164, 222, 264
supplementation .....	120, 165, 219, 222-223, 264, 268
vitamin K .....	121, 168, 171, 262
voluntary health organizations <i>see</i> bone health, promoting	
warning signs <i>see</i> “red flags”, risk assessment	
weight loss and bone health .....	130-131
Women’s Health Initiative (WHI) .....	120
World Health Organization .....	5, 6, 41, 76, 78, 204, 206, 267
wrist fractures	
costs .....	95
rehabilitation .....	240-241
treatment .....	238-239
X-linked hypophosphatemic rickets .....	53
young adults .....	254, 257
bone maintenance in .....	114, 118, 129
nutrition in .....	261-265
osteoporosis in .....	189
Z-scores .....	204, 206, 207, 261, 272
zinc .....	121, 168, 171
zoledronic acid .....	236, 243